UNISUS study design: a phase 3 superiority study comparing the efficacy, safety, and tolerability of macitentan 75 mg vs macitentan 10 mg in patients with pulmonary arterial hypertension (PAH)
28 August 2022 (17:15 - 17:45)
Organised by:
Abstract
Slides
About the speaker
University of Michigan, Ann Arbor (United States of America)
4 More presentations in this session
Doctor J. Barbera (Barcelona, ES)
Doctor A. Constantine (Birmingham, GB)
Professor H. Dai (Kunming, CN)
Access the full session
The Event
ESC Congress 2022
28 August 2022
17:15 CET
You may be interested in
Congress Presentation
